- Home
- CLDX vs SNDX Comparison
CLDX vs SNDX Comparison
Compare CLDX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- SNDX
- Stock Information
- Founded
- CLDX N/A
- SNDX 2005
- Country
- CLDX United States
- SNDX United States
- Employees
- CLDX N/A
- SNDX N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- SNDX Health Care
- Exchange
- CLDX Nasdaq
- SNDX Nasdaq
- Market Cap
- CLDX 1.6B
- SNDX 1.3B
- IPO Year
- CLDX 2008
- SNDX 2016
- Fundamental
- Price
- CLDX $26.77
- SNDX $14.35
- Analyst Decision
- CLDX Buy
- SNDX Strong Buy
- Analyst Count
- CLDX 9
- SNDX 11
- Target Price
- CLDX $43.78
- SNDX $38.55
- AVG Volume (30 Days)
- CLDX 958.4K
- SNDX 2.2M
- Earning Date
- CLDX 11-05-2025
- SNDX 11-04-2025
- Dividend Yield
- CLDX N/A
- SNDX N/A
- EPS Growth
- CLDX N/A
- SNDX N/A
- EPS
- CLDX N/A
- SNDX N/A
- Revenue
- CLDX $5,790,000.00
- SNDX $77,933,000.00
- Revenue This Year
- CLDX N/A
- SNDX $641.22
- Revenue Next Year
- CLDX N/A
- SNDX $110.64
- P/E Ratio
- CLDX N/A
- SNDX N/A
- Revenue Growth
- CLDX N/A
- SNDX 2126.66
- 52 Week Low
- CLDX $14.40
- SNDX $8.58
- 52 Week High
- CLDX $29.93
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- CLDX 56.87
- SNDX 36.65
- Support Level
- CLDX $26.10
- SNDX $14.69
- Resistance Level
- CLDX $27.87
- SNDX $16.04
- Average True Range (ATR)
- CLDX 1.18
- SNDX 0.84
- MACD
- CLDX -0.07
- SNDX -0.20
- Stochastic Oscillator
- CLDX 67.91
- SNDX 0.58
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.